

Terrorism and Disaster

WHAT
CLINICIANS
NEED TO
KNOW



Pneumonic Plague

 RUSH UNIVERSITY
MEDICAL CENTER



Sponsored for CME Credit by
Rush University Medical Center

Release Date: April 1, 2005
Expiration Date: March 31, 2007

Terrorism and Disaster

WHAT
CLINICIANS
NEED TO
KNOW

SERIES EDITORS

**Rush University
Medical Center
Chicago, Illinois**

Stephanie R. Black, MD*
Assistant Professor of Medicine
Section of Infectious Diseases
Department of Internal Medicine

Daniel Levin, MD*
Assistant Professor
General Psychiatry Residency Director
Department of Psychiatry

Gillian S. Gibbs, MPH*
Project Coordinator
Center of Excellence for Bioterrorism
Preparedness

Linnea S. Hauge, PhD*
Educational Specialist
Department of General Surgery

**AUTHORS
Rush University
Medical Center
Chicago, Illinois**

Stephanie R. Black, MD*
Assistant Professor of Medicine
Section of Infectious Diseases
Department of Internal Medicine

Daniel Levin, MD*
Assistant Professor
General Psychiatry Residency Director
Department of Psychiatry

**Uniformed Services University
Health Sciences
Bethesda, Maryland**

David M. Benedek, MD, LTC, MC, USA
Associate Professor of Psychiatry

Steven J. Durning, MD, Maj, USAF, MC*
Associate Professor of Medicine

Thomas A. Grieger, MD, CAPT, MC, USN*
Associate Professor of Psychiatry
Associate Professor of Military &
Emergency Medicine
Assistant Chair of Psychiatry for Graduate
& Continuing Education

Molly J. Hall, MD, Col, USAF, MC, FS*
Assistant Chair & Associate Professor
Department of Psychiatry

Derrick Hamaoka, MD, Capt, USAF, MC, FS*
Director, Third Year Clerkship
Instructor of Psychiatry

Paul A. Hemmer, MD, MPH, Lt Col, USAF, MC*
Associate Professor of Medicine

Benjamin W. Jordan, MD, CDR, MC, USNR, FS*
Assistant Professor of Psychiatry

James M. Madsen, MD, MPH, COL, MC-FS, USA*
Associate Professor of Preventive Medicine
and Biometrics
Scientific Advisor, Chemical Casualty Care
Division, US Army Medical Research Institute
of Clinical Defense (USAMRICD), APG-EA

Deborah Omori, MD, MPH, FACP, COL, MC, USA*
Associate Professor of Medicine

Michael J. Roy, MD, MPH, FACP, LTC, MC*
Associate Professor of Medicine
Director, Division of Internal Medicine

Jamie Waselenko, MD, FACP**
Assistant Professor of Medicine
Assistant Chief, Hematology/Oncology
Walter Reed Army Medical Center
Washington, DC

Guest Faculty

Ronald E. Goans, PhD, MD, MPH*
Clinical Associate Professor
Tulane University School of Public Health &
Tropical Medicine
New Orleans, LA

Sunita Hanjura, MD*
Rockville Internal Medicine Group
Rockville, MD

Niranjan Kanesa-Thanan, MD, MTMH*
Director, Medical Affairs & Pharmacovigilance
Acambis
Cambridge, MA

Jennifer C. Thompson, MD, MPH, FACP*
Chief, Department of Clinical Investigation
William Beaumont Army Medical Center
El Paso, TX

Faculty Disclosure Policy

It is the policy of the Rush University Medical Center Office of Continuing Medical Education to ensure that its CME activities are independent, free of commercial bias and beyond the control of persons or organizations with an economic interest in influencing the content of CME. Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest (including but not limited to pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic) within the preceding 12 months. If there are relationships that create a conflict of interest, these must be resolved by the CME Course Director in consultation with the Office of Continuing Medical Education prior to the participation of the faculty member in the development or presentation of course content.

* Faculty member has nothing to disclose.

**Faculty disclosure: CBCE Speaker's Core for SuperGen.

Pneumonic Plague

CASE AUTHOR: Jennifer C. Thompson MD, MPH, FACP

ACCREDITATION & DESIGNATION STATEMENT

Rush University Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Rush University Medical Center designates this educational activity for a maximum of 1 credit of category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CME credits are available free of charge through March 2007.

DISCLAIMER

This project was funded by the Metropolitan Chicago Healthcare Council (MCHC) through a grant from the Health Resources and Services Administration (HRSA).

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as representing the opinion of Rush University Medical Center, the Department of the Army, Department of the Navy, Department of the Air Force, Department of Defense, MCHC or HRSA.

FDA Approved Drug and Devices Assurance Statement

In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

INSTRUCTIONS

The questions that appear throughout this case are intended as a self-assessment tool. For each question, select or provide the answer that you think is most appropriate and compare your answers to the key at the back of this booklet. The correct answer and a discussion of the answer choices are included in the answer key.

Note: These self-assessment questions are not intended for CME credit. To apply for CME credit, you must complete the CME Test at the back of this booklet and submit it according to the directions provided.

In addition, a sign is provided in the back of this booklet for posting in your office or clinic. Complete the sign by adding your local health department's phone number.

Design and layout © 2005 Rush University Medical Center. The text contained herein falls under the U.S. Copyright Act of 1976 as a "U.S. Government Work" and is therefore considered Public Domain Information, however Rush University Medical Center reserves the right to copyright the design and layout of that information.

Pneumonic Plague

CASE AUTHOR: Jennifer C. Thompson MD, MPH, FACP

INTENDED AUDIENCE

Internal medicine, family medicine, and emergency medicine physicians, and other clinicians who will provide evaluation and care in the aftermath of a terrorist attack or other public health disaster

EDUCATIONAL OBJECTIVES

Upon completion of this case, participants will be able to:

- Describe the epidemiologic characteristics of plague that distinguish bioterrorist events from natural endemic outbreaks of disease.
- Describe the clinical features of pneumonic, septicemic, and bubonic plague.
- List the differential diagnoses of pneumonic plague and identify specimens and lab tests needed to confirm the diagnosis.
- Discuss the ramifications of a plague outbreak including healthcare workers' fear and absenteeism and depletion of healthcare teams.
- Describe infection control precautions and recommendations for notifying infection control and the local health department.
- Summarize basic treatment regimens, post-exposure prophylaxis, and management relevant to adult, pediatric, and pregnant patients with plague.

CASE HISTORY

A 29-year-old man from New Mexico was attending a professional conference in Washington, DC when he began experiencing abdominal pain, diarrhea, nausea, vomiting, and cough. He developed fever and chills and presented to a local primary care clinic. On evaluation he was febrile to 104°F and orthostatic. The lung examination was normal. The abdomen was soft and non-tender with slightly hyperactive bowel sounds. There was no lymphadenopathy. He was administered intravenous fluids and an anti-emetic for presumed gastroenteritis.

COMMENT: The presence of cough may be a subtle clue that this was not a typical case of gastroenteritis. However, it is easy to see how this symptom might have been missed or discounted in a busy acute care clinic. The challenge of diagnosing many agents of bioterrorism is that the initial signs and symptoms are often indistinguishable from common illnesses that are seen in day-to-day medical practice. Table 1 describes the 3 primary manifestations of plague and their associated differential diagnoses.

Table 1. Clinical Features of Plague

| | Bubonic | Pneumonic | Septicemic |
|------------------------|--|---|--|
| Exposure | Innoculation of bacteria from infected flea; exposure of abraded skin to contaminated tissue | Hematogenous spread to lungs during bacteremia associated with bubonic or septicemic plague; alternatively, primary pneumonic plague occurs after inhalation of bacteria during contact with person or animal with plague pneumonia | Same as bubonic or pneumonic plague |
| Incubation | 3-6 days | 1-5 days | 3-6 days |
| Pathophysiology | After inoculation, <i>Y. pestis</i> migrates to regional lymph nodes where aggressive intracellular multiplication occurs, resulting in enlargement, inflammation and associated hemorrhage with necrosis | Inhalation of aerosolized organisms into the lungs results in foci of infection | Rapid progression results in release of organisms causing overwhelming bacteremia prior to the development of lymphadenopathy; or enlarged lymph nodes may be internal (e.g. abdominal, mediastinal) and difficult to appreciate |
| Primary manifestations | Fever, malaise, focal lymphadenopathy (1 – 10 cm), often in femoral or inguinal areas that becomes extremely tender | Cough and hemoptysis, chest pain. Chest radiographs may demonstrate infiltrates, cavities or consolidation | Systemic toxicity with <i>Y. pestis</i> bacteremia |
| Other manifestations | May progress to sepsis syndrome with disseminated intravascular coagulation (DIC) | Gastrointestinal symptoms e.g. nausea, vomiting, diarrhea, abdominal pain may occur | DIC and acral necrosis may occur |
| Differential diagnosis | Staphylococcal, streptococcal or pasteuria infections Tularemia (<i>Francisella tularensis</i>) Cat scratch disease (<i>Bartonella henselae</i>) Chancroid (<i>Haemophilus ducreyi</i>) Lymphogranuloma venereum (<i>Chlamydia trachomatis</i>) Mononucleosis, CMV, Toxoplasmosis | Typical and atypical agents of community acquired pneumonia | Sepsis due to gram negative or gram positive agents, especially meningococemia, pneumococcal sepsis |

By the following morning the patient's condition had deteriorated, and he reported to a local emergency room complaining of weakness, cough, and chest pain in addition to gastrointestinal symptoms. He described a single episode a few hours earlier in which he had expectorated a small quantity of blood. He appeared extremely ill and was intermittently incoherent. His temperature was 104.4°F, and his blood pressure was 78/50 mm Hg. A chest radiograph revealed bilateral pulmonary infiltrates. The patient was admitted to the intensive care unit. Aggressive resuscitation was initiated with intravenous fluids in conjunction with empiric antibiotic therapy with piperacillin-tazobactam, azithromycin and vancomycin. He developed an increasing oxygen requirement that required endotracheal intubation and the implementation of mechanical ventilation. Gram stain of an endotracheal tube aspirate specimen showed numerous small gram-negative coccobacilli.




FIGURE 1. Wayson stain of peripheral blood in bacteremic *Y. pestis* infection demonstrating the characteristic bipolar (“safety pin”) staining. Figure from Centers for Disease Control and Prevention.

COMMENT: *Yersinia pestis* (*Y. pestis*) can readily be isolated from deep sputum specimens, tracheal aspirates, or bronchial washings of patients with pneumonic plague. In addition, patients may be bacteremic allowing for isolation of the organism from the blood. If the patient has CNS signs and symptoms, a lumbar puncture gram stain and culture may reveal the pathogen. The organism has a characteristic safety pin appearance (Figure 1) and will grow on most microbiology culture media, including MacConkey agar plates that are part of the routine laboratory workup of gram negative rods.

Over the next 36-48 hours, the patient remained febrile. The microbiology lab reported that their automated identification system was unable to identify the gram-negative rods that had been isolated from the tracheal aspirate. Manual biochemical assays were set up in order to make a definitive diagnosis.

The following day, the microbiology lab reported their suspicion that the isolated organism might be *Y. pestis*. The infectious disease attending physician was immediately notified.

QUESTION 1

What precautions are required while caring for a patient with suspected pneumonic plague?

- Standard precautions
- Contact precautions
- Droplet precautions
- Airborne precautions

Reminder: You can find the Answer Key & Discussion on page 8.

The proper precautions were implemented. Table 2 reviews the differences between droplet and airborne transmission. The hospital lab notified the local health department of their concern for *Y. pestis*, and the isolated organism was transported to their laboratory for definitive identification.

In the meantime, with a presumptive diagnosis of pneumonic plague, gentamicin, doxycycline, and ciprofloxacin were added to the patient’s antibiotic regimen; azithromycin was discontinued.

COMMENT: Streptomycin has traditionally been the treatment of choice for plague, since the drug has a strong, clinically tested record. However, the drug is not in frequent use today, and it is not widely obtainable, particularly on short notice. Gentamicin is much more readily available and considered to be an alternative agent. In situations where gentamicin and streptomycin are either unavailable or contraindicated, doxycycline, or chloramphenicol can be used. The fluoroquinolones have also demonstrated efficacy against the plague bacillus. Most of the available clinical data involve ciprofloxacin, and for this reason most authorities still recommend this drug as the first choice among fluoroquinolones. However, in vitro data suggest that levofloxacin would also be effective. Table 3 lists the doses of drugs that are used in the treatment of plague. Of note, several of these agents are relatively contraindicated in pregnant or lactating women or young children. However, in the event of a proven case of plague, the risks associated with these agents are outweighed by the benefits of therapy. It is generally recommended that patients receive at least 10 days of therapy, even though they may show clinical improvement and become afebrile within 4 – 5 days. In cases where the patient is critically ill, many clinicians will use a combination of agents (as in this case) in the hope of improving efficacy. Failure of therapy due to antimicrobial resistance in *Y. pestis* has not been a problem to date, but naturally occurring strains with multi-drug resistance have been isolated,² and the potential for genetic manipulation of the organism for use in a bioterrorist attack is unknown.

Table 2. Droplet Vs. Airborne Transmission

| Droplet Characteristics | Droplet Transmission | Airborne Transmission |
|--------------------------|---|---|
| Size | Large | Very small (5 microns or smaller) |
| Suspension in air | Do not remain suspended in air | Can remain suspended in the air, ie, airborne, for long periods of time |
| Dispersal | Travel short distances, 3 feet or less | Travel widely via air currents, ie, greater than 3 feet |
| Ability to infect others | Requires close contact (within 3 feet or less) between a patient and the susceptible individual | Does not require contact (within 3 feet or less); can be inhaled easily by a susceptible person |

Table 3. Recommended Regimens for the Treatment of Plague*

| Recommended Regimens | |
|----------------------|--|
| Adults | Streptomycin 30 mg/kg IM in 2 divided doses for a maximum of 2 gm/day Gentamicin 5 mg/kg/day IV or IM Gentamicin 2 mg/kg loading dose followed by 1.7 mg/kg IV or IM three times/day Doxycycline 100 mg IV two times/day Doxycycline 200 mg IV once/day Ciprofloxacin 400 mg IV two times/day Chloramphenicol 25 mg/kg IV four times/day |
| Children | Gentamicin 2.5 mg/kg IV or IM three times/day If \geq 45 kg, Doxycycline 100 mg IV two times/day If < 45 kg, Doxycycline 2.2 mg/kg IV two times/day Ciprofloxacin 15 mg/kg IV two times/day Chloramphenicol 25 mg/kg IV four times/day |

* Adapted from Inglesby et al.¹

A respiratory therapist caring for the patient commented that she had developed a cough and asked if she might have acquired pneumonic plague. Two nurses who had cared for the patient at the time of initial presentation reported flu-like symptoms and were worried that they too might have acquired plague. Another nurse, who was 4 months pregnant, refused to care for the patient because of fear that the droplet precautions that had been instituted would not provide adequate protection for her and her unborn baby.

COMMENT: It is critical to notify your infection control department and your local health department as soon as a case of plague is suspected or confirmed. Infection control practitioners and the hospital epidemiologist will determine the continued risk to people in the facility, as well as follow-up on any healthcare workers exposed to the source patient since admission. Table 4 reviews the recommended prophylactic regimens for people exposed to a patient with pneumonic plague.

Health department officials can often facilitate the transportation of specimens or isolates to a reference laboratory where a definitive identification can be made, and they will initiate the detailed and systematic investigation that is required in order to identify exposed individuals, and ascertain whether a bioterrorist event has occurred. Health department personnel are also trained in risk communication, a skill that can prove invaluable in the face of widespread panic and fear.

ABSENTEEISM⁴

In the United States, healthcare professionals have little experience in diagnosing and managing causalities caused by chemical, radiological, or biological agents. As a result, in the immediate aftermath of a bioterrorism event involving one of these agents, healthcare professionals may experience fear, shock, anger, helplessness, and may have concerns about the health and safety of their families and friends. Potentially, these feelings can contribute to absenteeism among the healthcare staff. For example, in 1994, during an outbreak of pneumonic plague in Surat, India, 80% of the private physicians fled the city.

Familiarity with chemical and biological agents, as well as training and drilling on your emergency plan may enhance performance by healthcare staff and help to minimize or prevent absenteeism.

Table 4. Prophylactic Regimens for People Exposed to a Patient With Pneumonic Plague*

| Post-exposure Prophylaxis | | |
|---------------------------|-------------|---|
| Adults | Recommended | Doxycycline 100 mg orally twice per day |
| | Recommended | Ciprofloxacin 500 mg orally twice per day |
| | Alternative | Chloramphenicol 25 mg/kg IV or orally four times per day |
| Children | Recommended | If \geq 45 kg, Doxycycline 100 mg orally twice per day |
| | Recommended | If $<$ 45 kg, Doxycycline 2.2 mg/kg orally twice per day to a maximum of 200 mg/day |
| | Recommended | Ciprofloxacin 20 mg/kg orally twice per day |
| | Alternative | Chloramphenicol 25 mg/kg IV or orally four times per day |

* Adapted from Inglesby et al.¹

QUESTION 2

An appropriate post-exposure intervention for people who have been in contact with a patient with pneumonic plague includes which of the following?

- Administration of the plague vaccine within 72 hours of exposure
- Administration of anti-plague immunoglobulin within 72 hours of exposure
- Administration of prophylactic antibiotics for 7 days

Two health department officials came to the hospital to assist with identification of contacts and to conduct an investigation into the source of the case. They reported that no other cases were confirmed or suspected in the local area.

QUESTION 3

Which of the following scenarios is most suspicious for a bioterrorist event?

- A 22-year-old college student and his girlfriend acquire bubonic plague while camping in Colorado.
- A 60-year-old businessman acquires pneumonic plague while attending a conference in New York City.
- A 49-year-old professor acquires septicemic plague while hunting prairie dogs in New Mexico.
- A 37-year-old housewife acquires pneumonic plague after her sick cat dies in Arizona.

COMMENT: The existence of even a single case of pneumonic plague in a non-endemic area should raise suspicion of an act of bioterrorism and requires further investigation. Table 5 compares characteristics of naturally occurring plague infections with the possible features of a bioterrorism event.

Table 5. Clinical and Epidemiologic Characteristics of Plague

| | Naturally Occurring Infection | Bioterrorism Event |
|-------------------------|---|---|
| Clinical manifestations | <ul style="list-style-type: none"> • Typically bubonic plague with occasional septicemic cases • Pneumonic plague is a relatively rare event that has been associated with infected cats | <ul style="list-style-type: none"> • Aerosolization of the plague bacillus would be expected to result in cases of pneumonic plague |
| Numbers of cases | <ul style="list-style-type: none"> • Isolated cases with common risk factors | <ul style="list-style-type: none"> • Large clusters of cases with a common mechanism of exposure |
| Geography | <ul style="list-style-type: none"> • Plague is enzootic in the southwestern United States. However, in an era of rapid and global travel, cases may potentially present anywhere, and a careful travel history is required to identify travel through or from an endemic area. | <ul style="list-style-type: none"> • Non-enzootic areas • Large metropolitan cities or locations of social, cultural, or political importance |
| Seasonality | <ul style="list-style-type: none"> • Most cases occur between April and October • Cases involving direct animal contact have occurred in the colder months (hunting season) | <ul style="list-style-type: none"> • None |
| Risk factors | <ul style="list-style-type: none"> • Working, camping, hunting outdoors, and in contact with fleas and/or host animals • Veterinarians and their staff who may be in contact with small animals in an enzootic area • Contact with domestic cats in an enzootic area • Communities with very poor hygiene/sanitation where rodents and fleas come in contact with humans • During rodent "die-offs" when infected fleas seek alternative hosts | <ul style="list-style-type: none"> • Non-specific |

One of the ICU nurses obtained the name and telephone number of the patient's housemate in New Mexico, and the health department officials called her as part of their investigation. She reported that the day before he left for his trip the patient had removed a stray cat from the crawlspace of their house. The cat had oral abscesses and lesions that, in retrospect, were consistent with feline plague. The animal died in the local animal shelter and was cremated without any diagnostic studies. While this information transpired, the local health department laboratory confirmed that the tracheal isolate was indeed *Y. pestis*. Once the isolate was identified and confirmed and susceptibility results were available, the infectious disease specialist narrowed the patient's antibiotic coverage.

COMMENT: As more information becomes available, it is evident that this case was unlikely to represent a bioterrorist event. Although the patient presented in Washington, DC, a likely target for a terrorist event, he lived in and traveled from New Mexico, where plague is enzootic. Additionally, he had a clear risk factor for pneumonic plague since he had made close contact with a sick cat that probably had feline plague. It was also reassuring that no other cases of plague were identified in the Washington, DC area; a terrorism event would likely result in a number of cases, rather than a single index case.

QUESTION 4

Other than isolating *Y. pestis* from a clinical specimen, what test is available to make the diagnosis of plague?

- a. When plague antigen is administered intra-dermally, people who have been infected with plague have a positive skin test that is analogous to the positive skin test in patients who have been exposed to tuberculosis.
 - b. People who have been infected with plague produce an antibody to the plague bacteria that can be detected in the serum.
 - c. People who have been infected with plague excrete a plague antigen that can be detected in the urine.
-

The patient made steady improvement and was successfully extubated on the 7th hospital day. He ultimately made a complete recovery and returned to work approximately 6 weeks after his initial presentation. Although over 30 people gave a history of close contact with him and received prophylactic antibiotics, no additional cases of plague were identified.

ANSWER KEY & DISCUSSION

QUESTION 1

What precautions are required while caring for a patient with suspected pneumonic plague?

- a. Standard precautions
- b. Contact precautions
- c. Droplet precautions
- d. Airborne precautions

ANSWER: The correct answer is c. Pneumonic plague may be transmitted from person-to-person via respiratory droplets if an infected individual is coughing. For this reason, it is recommended that droplet precautions and isolation be implemented for all patients with known or suspected plague until pneumonic plague has been ruled out, or until the patient has received at least 72 hours of effective therapy and made clinical improvement. Droplet precautions require the use of a surgical mask within 3 feet of an infected patient. Eye protection, in the form of goggles or face shields, is also recommended to protect the conjunctival mucosa. Standard precautions (formerly called universal precautions) are the precautions that are implemented in the care of all patients, and alone would not provide sufficient protection against transmission via the droplet route. Contact precautions involve the use of gowns and gloves and are used in infections such as methicillin-resistant *Staphylococcus aureus*, which is transmitted via fomites to the hands of health care providers. Airborne precautions require the use of an N95 respirator and a negative pressure environment. This is the form of protection that is required for infections such as pulmonary tuberculosis that result in the production of very small (1 – 10 μm) infectious nuclei that remain suspended in the air and can be inhaled into the pulmonary alveoli. There is no evidence of the formation of infectious particles of this size in pneumonic plague.¹

QUESTION 2

An appropriate post-exposure intervention for people who have been in contact with a patient with pneumonic plague includes which of the following?

- a. Administration of the plague vaccine within 72 hours of exposure
- b. Administration of anti-plague immunoglobulin within 72 hours of exposure
- c. Administration of prophylactic antibiotics for 7 days

ANSWER: The correct answer is c. Once a case of pneumonic plague has been diagnosed, it is necessary to identify individuals that have had close contact with the patient (defined as coming within 2 meters of the index case) prior to the completion of 72 hours of effective therapy. These individuals should receive post-exposure antibiotic prophylaxis for 7 days.¹ Table 4 gives the recommended prophylactic regimens for adults and children. Here again, it is necessary to balance the possible toxicities of these agents against the benefits of prophylaxis for special populations such as very young children and pregnant or lactating women. Close contacts that are receiving post-exposure prophylaxis antibiotics should be monitored for fever, development of cough, or other signs of illness. Should such signs develop, the patient should receive immediate medical attention with treatment for pneumonic plague on a presumptive basis until or unless this diagnosis can be definitively excluded. There is no plague vaccine currently available. Anti-plague immunoglobulin is not a commercially available product, and there are no data to support its role in post-exposure prophylaxis.

QUESTION 3

Which of the following scenarios is most suspicious for a bioterrorist event?

- a. A 22-year-old college student and his girlfriend acquire bubonic plague while camping in Colorado.
- b. A 60-year-old businessman acquires pneumonic plague while attending a conference in New York City.
- c. A 49-year-old professor acquires septicemic plague while hunting prairie dogs in New Mexico.
- d. A 37-year-old housewife acquires pneumonic plague after her sick cat dies in Arizona.

ANSWER: The correct answer is b. The existence of even a single case of pneumonic plague in a non-endemic area should raise suspicion of an act of bioterrorism and requires further investigation. Table 5 reviews some of the characteristics of naturally occurring plague infections for comparison with the possible features of a bioterrorism event.

QUESTION 4

Other than isolating *Y. pestis* from a clinical specimen, what test is available to make the diagnosis of plague?

- a. When plague antigen is administered intra-dermally, people who have been infected with plague have a positive skin test that is analogous to the positive skin test in patients who have been exposed to tuberculosis.
- b. People who have been infected with plague produce an antibody to the plague bacteria that can be detected in the serum.
- c. People who have been infected with plague excrete a plague antigen that can be detected in the urine.

ANSWER: The correct answer is b. Serologic testing can be used to confirm the diagnosis of plague retrospectively. The test available through the Centers for Disease Control and Prevention (CDC) detects the presence of anti-F1 antibody (antibody to the antigen of the bacterial envelope). The test is performed using paired serum with acute and convalescent or convalescent and post-convalescent specimens. A 4-fold or greater change in titer, or a single titer of 1:16 or greater is presumptive evidence of plague infection.³ There is no skin test for plague. There is also no diagnostic plague antigen that can be detected in the urine of infected patients.

REFERENCES

1. Inglesby TV, Dennis DT, Henderson, DA, et al. Plague as a biological weapon: medical and public health management. *JAMA*. 2000;283:2281–2290.
2. Galimand M, Guiyoule A, Gerbaud G, et al. Multidrug resistance in *Yersinia pestis* mediated by a transferable plasmid. *N Eng J Med*. 1997;337:677–680.
3. Perry RD, Fetherston JD. *Yersinia pestis*: etiologic agent of plague. *Clin Microbiol Rev*. 1997;10:35–66.
4. Ursano RJ, Norwood AE, Fullerton CS, Holloway HC, Hall M. Terrorism with Weapons of Mass Destruction: Chemical, Biological, Nuclear, Radiological, and Explosive Agents. In: Ursano RJ, Norwood AE, eds. *Trauma and Disaster Responses and Management*. Washington DC: American Psychiatric Association; 2003:145.

SUGGESTED READING

1. Gage KL, Dennis DT, Orloski KA, et al. Cases of cat-associated human plague in the western U.S., 1977–1998. *Clin Infect Dis*. 2000;30:892–900.
2. Inglesby TV, Dennis DT, Henderson, DA, et al. Plague as a biological weapon: medical and public health management. *JAMA*. 2000;283:2281 – 2290.
3. McGovern TW, Friedlander AM. Plague. In: Sidell FR, Takafuji ET, Franz DR, eds. *Medical Aspects of Chemical and Biological Warfare*. Washington DC: Borden Institute; 1997;479–502.
4. CDC Plague Home Page. Centers for Disease Control and Prevention. Available at: <http://www.cdc.gov/ncidod/dvbid/plague/index.htm>. Accessed December 17, 2004.
5. Infectious Diseases Society of America. *Yersinia pestis*. Available at: <http://www.idsociety.org/Template.cfm?Section=Bioterrorism>. Accessed December 17, 2004.

EVALUATION FORM

TERRORISM AND DISASTER: WHAT CLINICIANS NEED TO KNOW

Pneumonic Plague

Participant Information

| | | | |
|-------------------|-----------|--|--|
| Name/Degree _____ | | Practice setting: <input type="checkbox"/> Hospital/In-patient <input type="checkbox"/> Outpatient/Clinic <input type="checkbox"/> Other | |
| Address _____ | | Email _____ | |
| City _____ | | Clinical Specialty _____ | |
| State _____ | Zip _____ | Signature _____ | |
| Telephone _____ | | Date _____ | |

Instructions for Physicians Receiving Credit

The questions that follow may be used to obtain continuing medical education credit. To obtain 1 hour of Category 1 credit towards the AMA Physician’s Recognition Award, read this case study, which will take one hour of your time, circle the correct answer to each of the CME questions, complete the evaluation form, and return both the CME question page and the evaluation form via mail or fax to:

Rush University Medical Center
 Office of Continuing Medical Education
 600 South Paulina Street, Suite 433 AAF
 Chicago, Illinois 60612
 Fax: (312) 942-2000

Case Study Evaluation

Please rate this case study according to the following scale: 1=Very Poor 2=Poor 3=Fair 4=Good 5=Very Good 6=Excellent

1. Accredited CME activities must be “free of commercial bias for or against any product.” In this regard, how would you rate this activity? If you perceived any bias, please provide specific comments below. 1 2 3 4 5 6

2. How well did the case study satisfy your purpose for reading it?

3. To what extent were the stated objectives of the case study achieved?

4. In general, was the case study well organized and presented?

5. To what extent has this CME activity improved your preparedness to recognize and care for victims of a terrorism attack or other public health disaster?

6. What was your overall rating of this case study?

7. I would recommend this case study to a colleague. Yes No

8. Based upon your review of this case, what specific action(s) could you take to enhance disaster preparedness in your workplace? Please estimate the probability that you will act on this item (0-100% where 100% = certainty)

A. _____ A. _____

B. _____ B. _____

C. _____ C. _____

Please check this box if you prefer not to be contacted for follow-up about the impact of this activity on your clinical practice.

QUESTIONS FOR CONTINUING MEDICAL EDUCATION

- 1. Which clinical manifestation would be most likely after a bioterrorism incident involving aerosolization of plague?**
 - a. Bubonic plague
 - b. Septicemic plague
 - c. Pneumonic plague
 - d. Plague meningitis
- 2. Which of the following findings on gram stain is most consistent with *Y. pestis*, the etiologic agent of plague?**
 - a. Gram-positive branching filaments
 - b. Gram-negative coccobacilli
 - c. Gram-positive rods
 - d. Gram-negative diplococci
- 3. Which of the following regimens provides the best combination therapy for an adult patient with plague?**
 - a. Amikacin, dicloxacillin, ciprofloxacin
 - b. Streptomycin, dicloxacillin, ciprofloxacin
 - c. Gentamicin, doxycycline, ciprofloxacin
 - d. Streptomycin, chloramphenicol, trimethoprim-sulfamethoxazole
- 4. How long do patients with pneumonic plague require isolation and droplet precautions?**
 - a. For the duration of clinical illness
 - b. Until the chest x-ray abnormality has resolved
 - c. For at least 72 hours after the patient is no longer febrile and the cough has resolved
 - d. Until the patient has received at least 72 hours of effective therapy and has made clinical improvement
- 5. What is the best way to clinically manage people who have been in close contact with a patient with pneumonic plague?**
 - a. Prophylactic antibiotics for 7 days. If there is fever, cough or other signs of illness during this period, the patient needs to begin treatment for plague until or unless plague can be ruled out as the cause of the symptoms.
 - b. Close monitoring for 7 days. If there is fever, cough or other signs of illness during this period, the patient needs to begin treatment for plague until or unless plague can be ruled out as the cause of the symptoms.
 - c. Presumptive treatment for plague with droplet precautions until at least 72 hours of therapy have been administered.

Terrorism and Disaster

WHAT
CLINICIANS
NEED TO
KNOW

Rush University Medical Center faculty, in collaboration with faculty from the Uniformed Services University of the Health Sciences (USUHS) authored a case series to provide continuing medical education (CME) for terrorism preparedness and other public health emergencies.

A series of 14 case studies was developed to provide innovative learning opportunities for health professionals to problem-solve issues related to terrorism or other public health emergencies. Due to the complicated and volatile nature of a terrorist event, the case studies were designed to expand outside the clinician-patient interaction and involve:

- deploying outside resources
- notifying appropriate officials
- coordinating a response team
- dealing with media and concerned public
- initiating emergency/disaster plans

Each case provides the CME user with decision-making challenges within his or her discipline, along with scenarios that address broader interdisciplinary issues. This interdisciplinary approach is particularly important in disaster preparedness, when health professionals will likely be called on to work outside their day-to-day experiences.

Authored by experts in the field, each self-paced case includes a thorough case history, questions to test your knowledge, a resource list of additional readings and relevant websites. One-hour CME and CEU credit is available for each case, following the successful completion of the CME questions included with each case. The CME and CEU credit is available free of charge through March 2007.

The cases in the series include:

MEDICINE

The medicine cases address recognition of the agent, diagnosis, treatment, and medical case management.

- **Pneumonic Plague**
- **Radiation Attack**
- **Sarin**
- **Smallpox**
- **Staphylococcal Enterotoxin B**
- **Viral Hemorrhagic Fevers**

PSYCHIATRY

The psychiatry cases address issues of disaster psychiatry.

- **Emergency Mental Health After a Suicide Bombing**
- **Psychiatric Sequelae in a Survivor of 9/11**
- **Psychosocial Management of a Radiation Attack**

INTERDISCIPLINARY

The interdisciplinary cases address basic medical management, general disaster planning, communicating with the media and concerned public, and psychosocial case management.

- **Inhalational Anthrax**
- **Pulmonary Toxicants**
- **SARS**
- **Smallpox**
- **Viral Encephalitis**

For more information or to order your free copy of any of the cases in this series, please contact:

Office of Continuing
Medical Education
Rush University Medical Center
Suite 433 AAF
Chicago, Illinois 60612
Telephone: (312) 942-7119
Facsimile: (312) 942-2000
E-mail: cme_info@rush.edu

 RUSH UNIVERSITY
MEDICAL CENTER

